Seroepidemiology as basis for design of a human papillomavirus vaccination program

Vaccine

Volumn 26, Issue 41, 2008, Pages 5263-5268

  Ryding, J ^a   French, K M ^b   Naucler, P ^a   Barnabas, R V ^c   Garnett, G P ^b   Dillner, J ^a  

^a LUND UNIVERSITY   (Sweden)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c HIV Vaccine Trials Network   (United States)

Author keywords

Mathematical model; Serology; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CHILD; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; SEROPREVALENCE; SEXUAL BEHAVIOR; SWEDEN; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNIZATION PROGRAMS; MALE; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEROEPIDEMIOLOGIC STUDIES; SEXUAL BEHAVIOR; SWEDEN; VACCINATION; YOUNG ADULT;

EID: 50849092853     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.041     Document Type: Article

References (53)

1. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118 June 15 12 (2006) 3030-3044
2. Lowndes C.M. Vaccines for cervical cancer. Epidemiol Infect 134 1 (2006) 1-12
3. Laara E., Day N.E., and Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1 8544 (May 30) (1987) 1247-1249
4. Gustafsson L., and Adami H.O. Optimization of cervical cancer screening. Cancer Causes Control 3 2 (1992) 125-136
5. Hemminki K., Li X., and Mutanen P. Age-incidence relationships and time trends in cervical cancer in Sweden. Eur J Epidemiol 17 4 (2001) 323-328
6. Pettersson F., Bjorkholm E., and Naslund I. Evaluation of screening for cervical cancer in Sweden: trends in incidence and mortality 1958-1980. Int J Epidemiol 14 4 (1985) 521-527
7. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 6 (February 6) (2003) 518-527
8. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (1999) 12-19
9. zur Hausen H. Oncogenic DNA viruses. Oncogene 20 54 (November 26) (2001) 7820-7823
10. Longworth M.S., and Laimins L.A. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68 2 (2004) 362-372
11. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 1 (January 13) (2003) 63-73
12. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (November 21) (2002) 1645-1651
13. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6 11 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
14. Brown D.R., Fife K.H., Wheeler C.M., Koutsky L.A., Lupinacci L.M., Railkar R., et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22 21/22 (July 29) (2004) 2936-2942
15. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (April 15) (2006) 1247-1255
16. Arbyn M., and Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 38 3 (2007) 189-197
17. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3 5 (2006) e138
18. French K.M., Barnabas R.V., Lehtinen M., Kontula O., Pukkala E., Dillner J., et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 96 3 (February 12) (2007) 514-518
19. Wang S.S., Schiffman M., Shields T.S., Herrero R., Hildesheim A., Bratti M.C., et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10,000 women in Costa Rica. Br J Cancer 89 7 (October 6) (2003) 1248-1254
20. Viscidi R.P., Schiffman M., Hildesheim A., Herrero R., Castle P.E., Bratti M.C., et al. Seroreactivity to human papillomavirus (HPV) types 16 18 or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13 2 (2004) 324-327
21. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., and Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334 6 (February 8) (1996) 349-355
22. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., and Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350 9091 (November 29) (1997) 1569-1577
23. Olin P CR, Johansen K, Hallander H, Ljungman M, Svensson Å. Seroepidemiologisk tvärsnittsstudie 1997, Slutrapport. Smittskyddsinstitutets rapportserie 3:2004, 70 sidor, reviderad 2006 1997.
24. Grabowska K., Wang X., Jacobsson A., and Dillner J. Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels. J Immunol Methods 271 1/2 (December 20) (2002) 1-15
25. Ferguson M., Heath A., Johnes S., Pagliusi S., and Dillner J. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer 118 6 (March 15) (2006) 1508-1514
26. Silins I., Wang X., Tadesse A., Jansen K.U., Schiller J.T., Avall-Lundqvist E., et al. A population-based study of cervical carcinoma and HPV infection in Latvia. Gynecol Oncol 93 2 (2004) 484-492
27. Andersson-Ellstrom A., Dillner J., Hagmar B., Schiller J., Sapp M., Forssman L., et al. Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls A longitudinal cohort study. Sex Transm Dis 23 3 (1996) 234-238
28. Lewin BF-M, Kerstin H. elmius, Gisela Lalos, Ann Månsson, Sven-Axel. Sex in Sweden-On the Swedish Sexual Life. The National Institute of Public Health 1997.
29. Carter J.J., and Galloway D.A. Humoral immune response to human papillomavirus infection. Clin Dermatol 15 2 (1997) 249-259
30. Gissmann L. Immunologic responses to human papillomavirus infection. Obstet Gynecol Clin North Am 23 3 (1996) 625-639
31. Castle P.E., Shields T., Kirnbauer R., Manos M.M., Burk R.D., Glass A.G., et al. Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex Transm Dis 29 3 (2002) 82-87
32. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89 1 (July 7) (2003) 101-105
33. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16 18 and 6 capsid antibody responses following incident infection. J Infect Dis 181 6 (2000) 1911-1919
34. Ho G.Y., Studentsov Y.Y., Bierman R., and Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13 1 (2004) 110-116
35. Koutsky L.A., Holmes K.K., Critchlow C.W., Stevens C.E., Paavonen J., Beckmann A.M., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327 18 (October 29) (1992) 1272-1278
36. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 3 (February 1) (2003) 218-226
37. Woodman C.B., Collins S., Winter H., Bailey A., Ellis J., Prior P., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357 9271 (June 9) (2001) 1831-1836
38. Darroch J.E., Singh S., and Frost J.J. Differences in teenage pregnancy rates among five developed countries: the roles of sexual activity and contraceptive use. Fam Plan Perspect 33 6 (2001) 244-250 81
39. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. JAMA 297 8 (February 28) (2007) 813-819
40. Stone K.M., Karem K.L., Sternberg M.R., McQuillan G.M., Poon A.D., Unger E.R., et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186 10 (November 15) (2002) 1396-1402
41. Slavinsky III J., Kissinger P., Burger L., Boley A., DiCarlo R.P., and Hagensee M.E. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS 12 8 (2001) 516-523
42. Svare E.I., Kjaer S.K., Nonnenmacher B., Worm A.M., Moi H., Christensen R.B., et al. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J Infect Dis 176 4 (1997) 876-883
43. van Doornum G., Prins M., Andersson-Ellstrom A., Dillner J., and Immunoglobulin A. G and M responses to L1 and L2 capsids of human papillomavirus types 6 11 16 18 and 33 L1 after newly acquired infection. Sex Transm Infect 74 5 (1998) 354-360
44. Witkin S.S., Linhares I., Giraldo P., Jeremias J., and Ledger W.J. Individual immunity and susceptibility to female genital tract infection. Am J Obstet Gynecol 183 1 (2000) 252-256
45. Mestecky J., and Fultz P.N. Mucosal immune system of the human genital tract. J Infect Dis 179 Suppl. 3 (1999) S470-S474
46. Grossman C. Possible underlying mechanisms of sexual dimorphism in the immune response, fact and hypothesis. J Steroid Biochem 34 1-6 (1989) 241-251
47. Dillner J., Wiklund F., Lenner P., Eklund C., Frederiksson-Shanazarian V., Schiller J.T., et al. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer 60 3 (January 27) (1995) 377-382
48. Carter J.J., Koutsky L.A., Wipf G.C., Christensen N.D., Lee S.K., Kuypers J., et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174 5 (1996) 927-936
49. Eisemann C., Fisher S.G., Gross G., Muller M., and Gissmann L. Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups. J Gen Virol 77 Pt 8 (1996) 1799-1803
50. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10 11 (2004) 1915-1923
51. Brisson M., Van de Velde N., De Wals P., and Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 29 (July 20) (2007) 5399-5408
52. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 1 (2007) 28-41
53. Kohli M., Ferko N., Martin A., Franco E.L., Jenkins D., Gallivan S., et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 96 1 (January 15) (2007) 143-150